Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07299292
PHASE2
Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)
Sponsor: SMED Clinical Research
View on ClinicalTrials.gov
Summary
Hypothesis The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-12-01
Completion Date
2027-03-30
Last Updated
2025-12-23
Healthy Volunteers
No
Conditions
Interventions
DRUG
Abiraterone 250 mg with food + prednisone
Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases
Locations (3)
Hospital Carlos A Durand
Buenos Aires, Argentina
Hospital San José
Hermosillo, Spain
Instituto Oriente Boliviano
Santa Cruz de la Sierra, Spain